RapaLink-1

News alerts, weekly reports and conference planners

Company:

Revolution Medicines, University of California

Drug class:

mTOR inhibitor, mTORC1 inhibitor

MTOR A2034V	Breast Cancer	MTOR A2034V	Breast Cancer	RapaLink-1 Sensitive: D – Preclinical RapaLink-1 Sensitive : D	RapaLink-1 Sensitive: D – Preclinical RapaLink-1 Sensitive : D
MTOR M2327I	Breast Cancer	MTOR M2327I	Breast Cancer	RapaLink-1 Sensitive: D – Preclinical RapaLink-1 Sensitive : D	RapaLink-1 Sensitive: D – Preclinical RapaLink-1 Sensitive : D
MTOR F2108L	Breast Cancer	MTOR F2108L	Breast Cancer	RapaLink-1 Sensitive: D – Preclinical RapaLink-1 Sensitive : D	RapaLink-1 Sensitive: D – Preclinical RapaLink-1 Sensitive : D

Associations
(3)